U.S. Patent No. 10,485,771 B2 (‘771) issued on November 26, 2019, entitled ”Methods of Regulating Cannabinoid Receptor Activity-Related Disorders and Diseases.” It was issued to inventors Irving W. Wainer of Washington, DC, Michel Bernier of Pikesville, Maryland, and Rajib K. Paul of Baltimore, Maryland. The applicant/assignee is the U.S. Department of Health & Human Services, based in Bethesda, Maryland.
The specification discloses various embodiments for use of fenoterol analogues in regulation of CB receptor activity to treat various diseases, notably several types of cancers. The ‘771 claims are directed to the method of treating liver cancer, through administration of CB receptor-based compound comprising GPR55, and a dosing administration from 0.001 to 10.0 mg/kg body weight.
The following Figure is representative of the claimed invention:
The Cooperative Patent Classification is A61K, preparations for medical, dental, or toilet purposes, namely, medicinal preparations containing organic active ingredients, namely, Arylalkylamines, e.g., propranolol, tamoxifen, phenoxybenzamine (31/137) and (31/05); and medicinal preparations containing active ingredients not provided for in groups, namely, mixtures of active ingredients without chemical compositions, e.g., antiphlogistics and cardiaca (45/06).
The ‘771 patent is notable because the U.S. government is the applicant/assignee. This raises the unusual dichotomy between a cannabis patent and the illegality of the product, both procured as a result of a federal agency. This dichotomy has been exacerbated by the issuance of U.S. Patent No. 6,630,507, to the NIH. Notwithstanding, any entity can conceivably obtain an issued patent and that would include the government. Please contact Yonaxis for more information or if you have any questions.